
Sign up to save your podcasts
Or
We love to hear from our listeners. Send us a message.
Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive solid tumors and CLDN18.2-positive solid tumors. And they cover a realistic outlook on the evolution of cancer treatment.
Subscribe to the podcast!
Apple | Spotify | YouTube
4.9
3838 ratings
We love to hear from our listeners. Send us a message.
Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive solid tumors and CLDN18.2-positive solid tumors. And they cover a realistic outlook on the evolution of cancer treatment.
Subscribe to the podcast!
Apple | Spotify | YouTube
757 Listeners
177 Listeners
30,845 Listeners
3,195 Listeners
32,291 Listeners
2,648 Listeners
272 Listeners
318 Listeners
29 Listeners
2,135 Listeners
147 Listeners
18 Listeners
15 Listeners
54 Listeners
152 Listeners